Romani, Ilaria http://orcid.org/0000-0001-7966-3525
Nencini, Patrizia
Sarti, Cristina
Pracucci, Giovanni
Zedde, Marialuisa
Nucera, Antonia
Cianci, Vittoria
Moller, Jessica
Toni, Danilo
Orsucci, Daniele
Casella, Carmela
Pinto, Vincenza
Palumbo, Pasquale
Barbarini, Leonardo
Bella, Rita
Ragno, Michele
Scoditti, Umberto
Mezzapesa, Domenico Maria
Tassi, Rossana
Diomedi, Marina
Cavallini, Anna
Volpi, Gino
Chiti, Alberto
Bigliardi, Guido
Sacco, Simona
Linoli, Giovanni
Ricci, Stefano
Giordano, Antonello
Bonetti, Bruno
Rasura, Maurizia
Cecconi, Emanuela
Princiotta Cariddi, Lucia
Currò Dossi, Roberto
Melis, Marta
Consoli, Domenico
Guidetti, Donata
Biagini, Silvia
Accavone, Donatella
Inzitari, Domenico
Funding for this research was provided by:
Takeda Pharmaceutical Company (IIR-ITA-00977)
Università degli Studi di Firenze
Article History
Received: 6 June 2021
Accepted: 17 September 2021
First Online: 5 October 2021
Change Date: 18 February 2022
Change Type: Update
Change Details: OA funding note shall be added to the article to fulfill the contractual requirement of the Compact agreement.
Declarations
:
: The FSIR protocol was approved by the Ethical Committees of coordinating center (CEAVC: “Comitato Etico Area Vasta Centro” of Tuscany Region, Italy) and of each participating hospital. A written informed consent was required before enrollment. Due to the merely observational nature of the study, patients were expected to receive diagnostic procedures and therapies in agreement with Italian guidelines for stroke management and neurological FD recommendations.
: IR received travel grants from Sanofi-Genzyme, Takeda–Shire, and Amicus; PN received speaker’s honoraria from Takeda-Shire, Sanofi-Genzyme, and Amicus, MZ received travel and consultation grants from Takeda-Shire, Sanofi-Genzyme, and Amicus, DI receives speaker’s honoraria from Takeda-Shire. Other authors declared that they have no competing interests for FSIR study.